Ethic Inc. Buys 9,688 Shares of Gilead Sciences, Inc. $GILD

Ethic Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 103,445 shares of the biopharmaceutical company’s stock after buying an additional 9,688 shares during the period. Ethic Inc.’s holdings in Gilead Sciences were worth $15,418,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences in the second quarter valued at about $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. PFS Partners LLC increased its stake in shares of Gilead Sciences by 101.1% during the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 96 shares during the last quarter. Laurel Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $29,000. Finally, Wiser Advisor Group LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $30,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.4%

Shares of NASDAQ:GILD opened at $166.89 on Friday. The firm has a fifty day moving average price of $153.04 and a two-hundred day moving average price of $140.94. The company has a market cap of $207.00 billion, a price-to-earnings ratio of -52.81 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the prior year, the firm posted $2.47 earnings per share. The business’s quarterly revenue was up 6.8% on a year-over-year basis. Analysts anticipate that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is presently -103.80%.

Insiders Place Their Bets

In other news, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the transaction, the insider directly owned 118,234 shares of the company’s stock, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 239,310 shares of company stock valued at $38,945,617 over the last 90 days. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GILD shares. Sanford C. Bernstein reiterated an “outperform” rating and issued a $175.00 price objective on shares of Gilead Sciences in a research note on Monday, November 2nd. Scotiabank increased their price objective on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. BMO Capital Markets reissued an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a research report on Friday, October 30th. Wells Fargo & Company boosted their target price on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Cantor Fitzgerald boosted their target price on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.15.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.